First GLP-1 pill for weight loss, diabetes shows success in Eli Lilly trial

Injectables for type 2 diabetes and weight loss may soon become a thing of the past, thanks to a groundbreaking development by Eli Lilly. The pharmaceutical company recently announced the successful completion of a phase 3 trial for Orforglipron – the first small-molecule GLP-1 that can be taken as a once-daily oral pill.

The ACHIEVE-1 trial focused on evaluating the efficacy of Orforglipron in comparison to a placebo among adults with type 2 diabetes who had “inadequate glycemic control with diet and exercise alone.” The results were impressive, showing a significant reduction in A1C levels (blood sugar) by an average of 1.3% to 1.6% across different doses.

Moreover, more than 65% of participants who received the highest dosage of Orforglipron achieved an A1C level below or equal to 6.5%, which is considered below the threshold for diabetes by the American Diabetes Association. Additionally, participants experienced an average weight loss of 16 pounds, or 7.9%, with the highest dose of the drug. Importantly, the researchers noted that participants had not reached a weight plateau by the end of the study, indicating the potential for further weight loss.

The trial also highlighted the overall safety and tolerability of Orforglipron, which was found to be consistent with traditional injectable GLP-1s like Ozempic, Wegovy, Mounjaro, and Zepbound. If approved by the FDA, Eli Lilly is confident in its ability to launch Orforglipron globally without any supply constraints.

Eli Lilly’s CEO, David A. Ricks, expressed optimism about the potential of Orforglipron, stating, “As a convenient once-daily pill, Orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world.” The company plans to submit Orforglipron for weight management to global regulatory agencies by the end of 2025, followed by its submission for type 2 diabetes treatment in 2026.

This breakthrough in diabetes and weight management could revolutionize the way these conditions are treated, offering patients a more convenient and effective alternative to traditional injectables. With the promise of improved glucose control and weight loss, Orforglipron represents a significant advancement in the field of diabetes care. Stay tuned for further updates on this innovative medication.